Références - Des râles en fin de vie : une analyse biodynamique

[1] Morita T, Hirai K, Sakaguchi Y, Tsuneto S, Shima Y. Family perceived distress about appetite loss and bronchial secretions in the terminal phase. J Pain Symptom Manag 2004;27:98—9.

[2] Musgrave CF, Opstad J. Fluid retention and intravenous hydration in the dying. Palliat Med 1996;10:53.

[3] Morita T, Ichiki T, Tsunoda J, Inoue S, Chihara S. A prospective study on the dying process in terminally ill cancer patients. Am J Hosp Palliat Care 1998;15:217—22.

[4] Morita T, Tsunoda J, Inoue S, Chihara S. Risk factors for death rattle in terminally ill cancer patients: a prospective exploratory study. Palliat Med 2000;14:19—23.

[5] Viola R, Wells G, Peterson J. The effects of fluid status and fluid therapy on the dying: a systematic review. J Palliat Care
1997;13:41—52.

[6] Dunlop RJ, Ellershaw JE, Baines MJ, Sykes N, Saunders CM. On withholding nutrition and hydration in the terminally ill: has palliative medicine gone too far ? A reply. J Med Ethics
1995;21:141—3.

[7] Regnard C, Mannix K. Reduced hydration or feeding in advanced disease. Palliat Med 1991;5:161—4.

[8] Burge F, King D, Willison D. Intravenous fluids and the hospitalized dying: a medical last rite ? Can Fam Physician 1990;36:883—6.

[9] Belcher N. Pulling out the drip: an ethical decision in the terminally ill. Geriatr Med 1990:22—3.

[10] Cahill Jr GF. Starvation in man. Clin Endocrinol Metab 1976;5:397—415.

[11] Halperin ML, Rolleston RF. Clinical detective stories. A problem-based approach to clinical cases and acid-base metabolism. London and Chapel Hill: Portland Press; 1993.

[12] Siddiqui RA, Pandhya D, Harvey K, Zaloga G. Nutrition modulation of cachexia/proteolysis. Nutr Clin Pract 2006;21:155—67.

[13] Gougoux A. Physiologie des reins et des liquides corporels. Sainte-Foy, Québec: Éditions MultiMondes; 2005. [14]

[14]Michie H. Metabolism of sepsis and multiorgan failure. World J Surg 1996;20:460—4.

[15] Howard RL, Schrier RW. A unifying hypothesis of sodium and water regulation in health and disease. Horm Res 1990;34:118—23.

[16] Ellershaw JE, Sutcliffe JM, Saunders CM. Dehydration and the dying patient. J Pain Symptom Manage 1995;10:192—7.

[17] Kass MR, Ellershow J. Respiratory tract secretions in the dying patient: a retrospective study. J Pain Symptom Manage 2003;26:897—902. Des râles en fin de vie : une analyse biodynamique 17

[18] Ellershaw J, Smith C, Overill S, Walker SE, Aldridge J. Care of the dying: setting standards for symptom control in the last 48 h of life. J Pain Symptom Manage 2001;21:12—7.

[19] Benett M. Death rattle: an audit of hyoscine (scopolamine) use and review of management. J Pain Symptom Manage 1996;12:229—33.

[20] Wildiers H, Menten J. Death rattle: Prevalence, prevention and
treatment. J Pain Symptom Manage 2002;23:310—7.

[21] Kompanje EJ. 'Death rattle' after withdrawal of mechanical ventilation: practical and ethical considerations. Intensive Crit Care Nurs 2006;22:214—9.

[22] Wee BL, Coleman PG, Hillier R, Holgate SH. The sound of death rattle I: are relatives distressed by hearing this sound ? Palliat
Med 2006;20:171—5.

[23] Rousseau P. Nonpain symptom management in the dying patient. Hosp Physician 2002:51—6.

[24] Kelly L, O'Driscoll T. The occasional palliative care patient:
lessons we have learned. Can J Rural Med 2004;9:253—6.

[25] Watts T, Jenkins K. Palliative care nurses' feelings about death
rattle. J Clin Nurs 1999;8:615—6.

[26] Rees E, Hardy J. Novel consent process for research in dying
patients unable to give consent. BMJ (Clinical research ed) 2003;327:198.

[27] Lanne T, Lundvall J. Very rapid net transcapillary fluid absorption from skeletal muscle and skin in man during pronounced hypovolaemic circulatory stress. Acta Physiol Scand 1989;136:1—6.

[28] Lange H. Multiorgan dysfunction syndrome: how water might contribute to its progression. J Cell Mol Med 2002;6:653—60.

[29] Kleiber M. Der energiehaushalt von mensch und haustier. Hamburg et Berlin: Paul Parey; 1967.

[30] Anonymous. Scopolamine: new preparations. Reference treatment for death rattle. Prescrire Int 2001;10:99—101.

[31] Lawrey H. Hyoscine vs glycopyrronium for drying respiratory secretions in dying patients. Br J Commun Nurs 2005;10:421—4;6.

[32] Back IN, Jenkins K, Blower A, Beckhelling J. A study comparing
hyoscine hydrobromide and glycopyrrolate in the treatment of death rattle. Palliat Med 2001;15:329—36.

[33] Bennett M, Lucas V, Brennan M, Hughes A, O'Donell V, Wee B. Using anti-muscarinic drugs in the management of death rattle: Evidence-based guidelines for palliative care. Palliat Med 2002;16:369—74.

[34] Hugel H, Ellershaw J, Gambles M. Respiratory tract secretions
in the dying patient: a comparison between glycopyrronium and hyoscine hydrobromide. J Palliat Med 2006;9: 279—84.

[35] Spiess JL, Scott SD. Anticholinergic agents for the treatment of ''death rattle'' in patients with myasthenia gravis. J Pain Symptom Manage 2003;26:684—6.